Icatibant acetate
Icatibant acetate structure
|
Common Name | Icatibant acetate | ||
|---|---|---|---|---|
| CAS Number | 138614-30-9 | Molecular Weight | 1364.57000 | |
| Density | 1.6g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C61H93N19O15S | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
Use of Icatibant acetateIcatibant acetate (HOE-140 acetate) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively[1][2][3]. |
| Name | Icatibant acetate |
|---|---|
| Synonym | More Synonyms |
| Description | Icatibant acetate (HOE-140 acetate) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Icatibant (10-30 μM) potentiates angiotensin III, but not angiotensin II (contraction mediated by angiotensin AT1 receptors), and Lys-des-Arg9-bradykinin, but not des-Arg9-bradykinin (effects mediated by the bradykinin B1 receptors)[3]. |
| In Vivo | Icatibant (10-30 μM) potentiates angiotensin III, but not angiotensin II (contraction mediated by angiotensin AT1 receptors), and Lys-des-Arg9-bradykinin, but not des-Arg9-bradykinin (effects mediated by the bradykinin B1 receptors)[3]. Animal Model: Female mice of the CBA/J (H-2k) strain[2]. Dosage: 0.06, 0.3, or 1.5 mg/kg. Administration: Subcutaneous administration twice daily. Result: The length of the large intestine was 93.6±6.8 mm with the 1.5 mg/kg dosage and 94.0±4.1 mm with the 0.3 mg/kg dosage , showing a significant preventive effect on shortening. |
| References |
| Density | 1.6g/cm3 |
|---|---|
| Molecular Formula | C61H93N19O15S |
| Molecular Weight | 1364.57000 |
| Exact Mass | 1363.68000 |
| PSA | 581.76000 |
| LogP | 1.67610 |
| Storage condition | -20℃ |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
|
Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.
Clin. Pharmacol. Ther. 93(4) , 326-34, (2013) Bradykinin increases during cardiopulmonary bypass (CPB) and stimulates the release of nitric oxide, inflammatory cytokines, and tissue-type plasminogen activator (t-PA), acting through its B2 recepto... |
|
|
Interaction between bradykinin and natriuretic peptides via RGS protein activation in HEK-293 cells.
Am. J. Physiol. Cell Physiol. 303(12) , C1260-8, (2012) In this study, the interaction of natriuretic peptides (NP) and bradykinin (BK) signaling pathways was identified by measuring membrane potential (V(m)) and intracellular Ca(2+) using the patch-clamp ... |
|
|
Influence of kinin peptides on monocyte-endothelial cell adhesion.
J. Cell. Biochem. 115(11) , 1985-95, (2014) Adhesion of leukocytes to vascular endothelium in response to proinflammatory mediators is an important component of the overall inflammatory reaction. In the current work, we used a retinoic acid-dif... |
| Icatibant acetate |